Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.

Clinical pharmacology and therapeutics - 1 Jul 2003

Thijssen Henk H W, Ritzen Bas

Abstract excerpt

BACKGROUND AND OBJECTIVES: Cytochrome P450 (CYP) 2C9 is one of the major CYP enzymes involved in the biotransformation of drugs, among others, the oral anticoagulant acenocoumarol. The enzyme has several polymorphisms, with the CYP2C9*2 and CYP2C9*3 variants most commonly present in white patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Adolescent
Share to Analysis of Variance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Aryl Hydrocarbon Hydroxylases

Share to Cytochrome P-450 CYP2C9

Share to Genotype

Share to Stereoisomerism

Source

Identifiers

PMID: 12844136
DOI: 10.1016/S0009-9236(03)00088-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12844136-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.PMID 12844136Read ↗

Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol pharmacodynamics.Semantic proximity Read ↗

CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.Semantic proximity Read ↗

Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.Semantic proximity Read ↗

Acenocoumarol stabilization is delayed in CYP2C93 carriers.Semantic proximity Read ↗

Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.Semantic proximity Read ↗

The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendationsSemantic proximity Read ↗

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.Semantic proximity Read ↗

[Pharmacogenetics and interindividual variability in drug response: cytochrome P-450 2C9 and coumarin anticoagulants].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.